Ricki Lewis

Thanks to biotechnology, immunotherapy has become standard of care along many a cancer patient's journey, with many targeted drugs now available. One of the oldest and most successful immunotherapies is simpler: a tamed version of a classic vaccine, against the infectious disease tuberculosis (TB).

"BCG" is the "treatment" vaccine's technical name, for Mycobacterium bovis Bacillus Calmette-Guérin. Oncologists have used BCG to treat early stage bladder cancer for decades.

A research team led by Rita Fior at the Champalimaud Centre for the Unknown, Lisbon, Portugal, figured out how BCG decimates cancer cells. Their report appears in Disease Models and Mechanisms. First author is Mayra Martínez-López, who was a PhD student at the lab and is now at the Universidad de las Américas in Quito, Ecuador.

Immunotherapy Began with Coley's Toxins

Retooling vaccines to kill cancer cells is a classic tale in the history of medicine.

A urine test for DNA pieces bearing 10 key mutations can indicate early inklings of bladder cancer, according to a report at the European Association of Urology meeting in Milan last month. Urothelial carcinoma is the most common type of bladder cancer, according to the National Cancer Institute.

The technique is called urinary comprehensive genomic profiling (uCGP). It copies telltale DNA sequences in urine, using a tool called "UroAmp," developed at Convergent Genomics. Like other cancers tests, it is being pioneered on people who already have the cancer to detect recurrence or response to treatment. If validated on many patients, the test might then be used for screening – that is, as part of the initial diagnostic process.

To continue reading, go to DNA Science, where this post first appeared.